Dr. Lei Zhu, Walter Reed Army Institute of Research, Clinical Trials Center, research coordinator prepare samples prior to the RV575 research study, Sept. 27, 2022. In October, the U.S. Military HIV Research Program will launch the Phase 1 study, evaluating varying doses of the Army's novel ALFQ adjuvant in a candidate HIV vaccine to determine the optimal adjuvant dosage level. (U.S. Army photo by Mike Walters/ Released)